cangrelor

platelet P(2T) receptor antagonist

Also Known As:

AR C69931MX; AR-C69931MX; Kengreal; N(6)-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic acid monoanhydride with dichloromethylenebis(phosphonic acid); cangrelor tetrasodium

Networked: 262 relevant articles (30 outcomes, 79 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleotides: 140
        Adenine Nucleotides: 1066
        Adenosine Monophosphate: 5507
        cangrelor: 262
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Ribonucleotides: 307
    - Adenine Nucleotides: 1066
      - Adenosine Monophosphate: 5507
        cangrelor: 262
  - Purine Nucleotides: 140
    - Adenine Nucleotides: 1066
      - Adenosine Monophosphate: 5507
        cangrelor: 262

Experts

1.	Bhatt, Deepak L: 43 articles (03/2022 - 12/2009)
2.	Stone, Gregg W: 34 articles (03/2022 - 12/2009)
3.	Mahaffey, Kenneth W: 33 articles (03/2022 - 12/2009)
4.	Harrington, Robert A: 32 articles (03/2022 - 03/2006)
5.	Prats, Jayne: 31 articles (03/2022 - 01/2012)
6.	White, Harvey D: 31 articles (03/2022 - 12/2009)
7.	Gibson, C Michael: 29 articles (03/2022 - 12/2009)
8.	Price, Matthew J: 29 articles (03/2022 - 01/2012)
9.	Hamm, Christian W: 26 articles (03/2022 - 05/2012)
10.	Deliargyris, Efthymios N: 20 articles (03/2022 - 03/2015)

Related Diseases

1.	Hemorrhage 11/15/2018 - "Cangrelor treatment is not only feasible and effective in resuscitated patients, but also inhibited platelet function more effectively than orally administered P2Y12-inhibitors without an increased event rate for bleeding." 07/01/2023 - "The ARCANGELO study aims to assess the safety of cangrelor on bleeding and the effects of the transition to oral P2Y12 inhibitors in a real-world setting according to the European Medical Agency's requirement. " 09/01/2022 - "The safety of cangrelor after the transition to oral P2Y12 inhibitors was evaluated as the incidence of bleeding outcomes in the 30 days following PCI according to postauthorization safety study guidelines. " 12/01/2021 - "We reviewed the use of cangrelor for antiplatelet bridging in real-world clinical scenarios and observed higher rates of clinically significant bleeding than seen in other similar studies. " 12/01/2021 - "Trials conducted in the United States of America have identified cangrelor as a potent and rapid-acting intravenous P2Y12 inhibitor, which has the potential of reducing ischemic events in these patients without an increase in the bleeding. "
2.	Thrombosis (Thrombus) 01/01/2022 - "Our study suggests that a cangrelor dose of 0.1 mcg/kg/min is associated with therapeutic PRU and prevents shunt thrombosis in neonates post systemic-to-pulmonary artery shunt, with minimal hemorrhagic complications." 03/15/2023 - "101 patients (56 men; median age (IQR) 59 (51-70) years) received low dose cangrelor for acute stenting (79/101 (78%)) and intraprocedural thrombus (22/101 (22%)). " 01/01/2022 - "Cangrelor Dosing and Monitoring for Prevention of Acute Systemic-to-Pulmonary Artery Shunt Thrombosis in Neonates." 01/01/2021 - "Cangrelor PK/PD analysis in post-operative neonatal cardiac patients at risk for thrombosis." 01/01/2020 - "Impact of Cangrelor on Coronary Thrombus: Optical Coherence Tomography Assessment."
3.	Myocardial Infarction 09/01/2013 - "To reassess the efficacy of cangrelor efficacy using the universal definition of myocardial infarction (MI). " 01/01/2019 - "Furthermore, administration of cangrelor prior to reperfusion has been shown in pre-clinical studies to reduce myocardial infarct (MI) size. " 09/06/2016 - "We explored the effects of cangrelor on myocardial infarction (MI) using different definitions and performed sensitivity analyses on the primary end point of the trial. " 02/01/2012 - "Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction." 01/01/2022 - "In phase 2, data were collected in a 2:1 (cangrelor-: non-cangrelor-treated) ratio of patients with myocardial infarction (n=873). "
4.	Acute Coronary Syndrome 11/23/2023 - "Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis." 11/15/2016 - "We aimed to study platelet inhibition during treatment with cangrelor and transition phase with oral P2Y12-receptor inhibitors in patients with acute coronary syndromes (ACS). " 06/01/2001 - "Phase II studies of intravenous AR-C69931MX in patients with acute coronary syndromes show that this agent has a rapid onset of action, rapidly achieving steady-state inhibition of platelet aggregation, with a half-life of only a few minutes. " 03/01/2001 - "Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes." 11/15/2023 - "Cangrelor - Expanding therapeutic options in patients with acute coronary syndrome."
5.	Ischemic Stroke 01/01/2021 - "The study objective was to evaluate the safety and efficacy of intravenous cangrelor in patients with acute ischemic stroke requiring urgent antiplatelet effect. " 12/01/2021 - "Use of intravenous cangrelor and stenting in acute ischemic stroke interventions: a new single center analysis and pooled-analysis of current studies." 12/01/2021 - "Overall, 129 patients who received IV cangrelor during an acute ischemic stroke intervention were identified. " 12/01/2021 - "A prospectively maintained database was reviewed to identify all cases of IV cangrelor administration during acute ischemic stroke intervention. " 06/01/2021 - "Cangrelor might be a safe and effective antiplatelet medication owing to its on/off activity for acute stenting in the setting of acute ischemic stroke. "

Related Drugs and Biologics

1.	Clopidogrel (Plavix)
2.	Prasugrel Hydrochloride
3.	Ticagrelor
4.	Glycoproteins (Glycoprotein)
5.	Tirofiban (Aggrastat)
6.	Eptifibatide (Integrilin)
7.	Aspirin (Acetylsalicylic Acid)
8.	elinogrel
9.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
10.	Adenosine Diphosphate (ADP)

Related Therapies and Procedures

1.	Stents
2.	Percutaneous Coronary Intervention
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Thrombectomy
5.	Heart-Assist Devices